Hamdard Laboratories: Boosting Health and Immunity through Unani Medicine

Hamdard Laboratories: Boosting Health and Immunity through Unani Medicine

Abdul Majeed & Asad Mueed, Chairman & Managing Trustee, Hamdard Laboratories

 Abdul Majeed & Asad Mueed, Chairman & Managing Trustee, Hamdard Laboratories

In an interaction with India Pharma Outlook, Abdul Majeed, Chairman & Managing Trustee, Hamdard Laboratories (Medicine Division), and Asad Mueed, Executive Trustee, Hamdard Laboratories (Medicine Division) share their views on the current market of natural medicine and the role played by Hamdard Laboratories in taking Unani medicine to the masses.

How do you see the shift from modern medicine to natural medicine, especially in the post-pandemic scenario?

Abdul Majeed: Unani as a system of medicine was started by Greeks and after the fall of the Greek Empire, it was adopted by the Arabs. If you look at the history, Hakim Ajmal Khan and my great grandfather Hakeem Hafiz Abdul Majeed, my grandfather Hakim Abdul Hameed, my father Abdul Mueed; these were the people, who brought it to India and because of their efforts, it was incorporated within the health ministry of India under the Ministry of AYUSH. Unani, after the Greeks and the Arabs, is only surviving in India. It is flourishing and developing in India, and that speaks volumes for our society and our culture as such, because the Indian culture has absorbed everything, whether it originated in India or not. During the Covid-19 pandemic, we have seen a very big shift of the consumers towards the herbal system of medicine of Unani and Ayurveda and this has been like a shot in the arm for these systems of medicine. Increasingly, people have also started realizing that allopathy can only give you temporary relief, but if you have to become internally strong and make your immune system strong, these herbal medicine systems are most effective. So, this is a big shift we have seen and we have to now prove ourselves to the millennial customers. And to achieve that we have to be effective, innovative and economical, and have to come closer to the consumer and these are the three most important mantras to be followed.

How do you see the current positioning of Hamdard Laboratories in the market and what role is it playing in bringing about a positive change in the manufacturing of natural products?

Abdul Majeed:We are positioned today as pioneers of Unani in India. Hamdard and Unani are synonymous with each other, and that is because Hamdard Laboratories is a charitable institution and its basic objective is the propagation and scientific development of the Unani system. So, I think the credit goes to our ancestors for bringing it to where we are, today. But as the times have changed very fast, we at Hamdard have always tried to emphasize the quality. We follow a policy of providing top-notch quality medicine at the most affordable price. That is our objective at this point of time. The technology that we have implemented into our production at our facilities has changed the way we produce and manufacture medicine and it is one of our biggest achievements today. The machinery and equipment we use to manufacture medicines are at par with allopathy, if not better. Eventually, Hamdard has also forayed into backward integration that we have in our facilities where we are buying agricultural land and we are cultivating the herbs. Getting into cultivation of active ingredients and basic herbal plants and adopting state-of-the-art technology is what we are trying and we have been successful in that as well. Although, some of the processes are still manually driven, we are looking into their automation in the coming days.

When it comes to quality assurance, how do you ensure that the quality of production meets the requisite standards?

Abdul Majeed: We have one of the best analytical facilities that any herbal plant would have today. What we are trying to do starts from the identification of the right herbal plant. So, the first issue is to identify the exact species that you need for the production of that particular medicine. That is the first step towards attaining the right kind of alkaloids that you need in your medication. We have one of the best facilities for the identification of these plants and herbs. And, we have a quality system in place. Hamdard has already gone through a transformation through which we have put all the procedures, systems and the SOPs in a digitized platform. The quality department is so structured in Hamdard that all herbal medicines which are received go through the mandatory testing for the right kind of species and the right kind of quality that we need. At every stage, there is a check and balance in place, so that the final product that is going to the consumer has the right kind of efficacy and quality it is supposed to have. So, this is how we have structured ourselves.

Please tell us about Hamdard’s Research and Development capability. How does it marry the ancient medicine science with the modern one?

Asad Mueed: Hamdard is an organization that has thrived by cherishing the traditional Unani system and also scientifically validating ancient knowledge in parallel. In fact, the research-based development of Unani Medicines is seeded by our great founders especially by Late Hakim Abdul Hameed Sb. at Hamdard which is

now deep-rooted in our ethos. Establishing Jamia Hamdard University is just a testimonial of our great visionary leader who had dreamt that only a combination of academia and industry can bring innovative advancement in spreading the natural treasure of health solutions to the masses. Later on, under the patronage of Late Hakim Abdul Hameed Sb. his elder son Late Mr. Abdul Mueed Sb. has envisaged the importance of adopting scientific advancements and redefining the traditional Unani system with a modern approach. Since we are the industry leader in the Unani system of medicine, we always focus on strengthening our in-house research capabilities. We have created an advanced research infrastructure at Hamdard where the age-old traditional knowledge is being validated through various steps of methodologies adopted for the scientific and systematic development of herbal medicines. We have also maintained a combination of experienced Hakeems and Vaidyas along with research scientists having M.Sc, M.Pharm and a Ph.D. degree in botany, analytical chemistry, pharmacy, and phytochemistry disciplines in our R&D. This amalgamation of traditional and modern scientific skills with the backing of advanced instrumentation is the basis of our research-based products on which we have earned the trust of our consumers since our inception.

How do you synchronize R&D, Quality Assurance, and Quality Control in order to streamline the complete process from innovation to deployment of the products?

Asad Mueed:Research and Development, Quality Assurance, and Quality Control are the backbone of any industry. Specifically in the field of Herbal medicines and Pharmaceuticals, it becomes important that these functions must remain in close coordination for ensuring a successful product lifecycle. At Hamdard, we follow global standards for the preparation of both Generic and Patent or Proprietary products. Innovation is both market-driven and based on current healthcare needs. In a true sense, we also focus on therapeutic areas where Unani System has an edge over other systems. All these activities pass through the stage-gate process and acceptance by the in-house innovation council. After scientific development of a product and establishing its safety and efficacy by R&D, it is scaled-up in our state-of-the-art pilot facility and finally, technology transfer is executed. It is followed by batch validation in production under the supervision of the validation team. Strict adherence to set guidelines by R&D is fulfilled by Quality Control and Quality Assurance team in coordination with production and engineering teams. Such validated processes are further followed in routine production processes ensuring high-quality products.

How is Hamdard Wellness fulfilling its commitment to provide selfless healthcare in order to improve the quality of human life?

Asad Mueed:Its main objective is to help address the unmet medical needs of millions of patients and to go beyond servicing the Unani-loving community with affordable quality products and spread the network to increase the accessibility of the Unani system of medicines. To achieve this commitment, Hamdard has established core values and lives by its philosophy that provides the foundations for all of our products and services. Unani system of medicine is a comprehensive medical system, providing promotive, preventive, curative, and rehabilitative healthcare and we are providing the entire spectrum with an assurance of safety, purity, and efficacy to improve the quality of human life.

What role is Hamdard Institute of Medical Sciences & Research (HIMSR) playing in the field of education?

Asad Mueed:HIMSR has been nationally recognized as an institute that demonstrates a high standard of Undergraduate and Post-Graduate Medical Education. According to NIRF ranking 2020, it has been ranked 22nd in the medical category. As a center of excellence in medical education, HIMSR offers courses at Undergraduate, Post-Graduate, and Post-Doctoral levels in medical and allied subjects. Based in Hamdard Nagar in New Delhi, it is an ambitious project aimed at modern life sciences and health domains and providing quality healthcare at an affordable cost. Deemed as a self-financing, unaided private institute, HIMSR is designed to become a parallel private healthcare system.

What are the major attributes of Hamdard which will ensure that it continues to be the leader in this segment?

Abdul Majeed: We are charting out the next five years' strategy and we are going through extensive research. We are conducting the research in two forms. One is talking to the consumers of the future generation. We are talking to the practitioners, doctors, and Hakeems. We are trying to understand what these systems of medicines mean today, and how these systems of medicines can be provided to the consumers of the next generation. The second part is that we are identifying our key herbs, which we are eventually planning to cultivate. Moreover, we already have eight clinics throughout India and we are planning to open at least 50 more clinics in the next three years. As most of the ailments are being placed in the medical remedies act, our clinics will play a crucial role. I believe that both Ayurveda and Unani have to be ready for that change once it happens. As for Hamdard, the main focus has always been on two things: health and education. We are spending 85 percent of whatever we are earning from Hamdard Laboratories into education and health. Our organization is devoted to the health and education of the people of India. We intend to remain focused on it in the future as well and that is the legacy we have to live up to.

on the deck

Most Viewed

Addressing Antimicrobial Resistance (AMR) Through Collaborative Efforts Fostering a Quality Culture in the Pharmaceutical Industry Advancements in Computer-Aided Drug Design for Pharmaceutical Research Why India is Gaining Popularity for Clinical Trials The Future of Kidney Transplants in India Usage of Conversational AI in the Health Insurance Sector Strategies for India to Reduce Its API Dependence on China Business Impact of USFDA Approvals on Indian Pharma Companies Innovative Strategies for Expanding Access to Life Saving Healthcare Solutions Badhal Village Crisis: How Rapid Diagnostics Could Have Saved Lives Why India is a Hotspot for Biotech Startups? Why Adapting Flexibility in IP Rights will Drive Generics Market Meeting the Challenges of High-Potency API (HPAPI) Production Impact of Human Factors Engineering on Medical Device Safety The Future of Pharma: Embracing Continuous Manufacturing The Role of Orphan Drugs in Treating Rare Diseases Emerging Technologies Shaping the Future of Drug Formulation Strategies for Optimizing Pharmaceutical Supply Chain Efficiency The Future of Medicine: Harnessing the Power of RNA-based Therapeutics AI in Medicine: Unmasking the Myths and Embracing the Transformative Reality Cycle Pharma Acquires Banner Life Sciences WHO's First-ever Global Summit on Traditional Medicine Starts in Gujarat The Importance of Data Integrity in Pharmaceutical Quality Control DCGI in Talks with Stakeholders to Develop a Standardised Web Platform to Assure Drug Quality and Patient Safety Glenmark Pharmaceuticals secures ANDA Nod for 0.03 per cent Tacrolimus Ointment Streamlining Laboratory Operations with a Modern LIMS Healthtech Start-up Suraksha QR Ropes In Actor Murali Sharma as its Brand Ambassador Unlocking the Potential of Pharmacogenomics: Enhancing Drug Safety and Efficacy The Impact of Pharmaceutical Testing on Drug Development India has Identified Three Health Priorities to Strengthen Global Health Infrastructure, says WHO National Health Authority launches 100 Microsites Project to Speed Up Digital Health Adoption India Should Partner with Australia to avail PBS for the Selection, Listing, and Pricing processes of exported drugs, says Sudarshan Jain Zydus Lifesciences India More than Doubles Profit Due to Increased Sales in the US India Triples Organ Donations over Past Decade says Union health minister Mansukh Mandaviya Advent Therapeutics Awarded $3 Million NIH Grant For Novel Neonatal Lung Therapy Three Pharma Marketing Strategies That Drive Sales Novartis Targets India's Rare Disease Market with 17 Clinical Programs UK Health Regulator approves GSK's Vaccine for the common respiratory virus RSV WHO Urges Increased Use Of Recommended Malaria-Fighting Tools Karnataka Budget Offered a Significant Boost to Health & Lifesciences Start-ups with Focus on Infrastructure & Innovation Three High Potential Moonshot Project Areas in Pharma CCI approves Bharat Biotech International-Eastman Exports deal How Biotech is Revolutionizing the Fight Against Cancer LifeCell and HaystackAnalytics ink strategic pact to scale-up TB whole genome sequencing pan-India Mankind Pharma IPO To Open On April 25 With A Price Fixed At Rs 1,026-1,080 Per Share US CDC Approves Second Omicron-Updated COVID Booster For Adults Three Trends that will Impact Pharmaceutical Industry in 2023 ModeX Therapeutics Commences Phase I EBV Vaccine Trial with Merck Designing Impactful Leadership and Talent Management Programs with Strategies for Success Novo Nordisk and Valo Health Partner to develop novel Treatments FOPE Calls for Extended Deadline for Schedule M Compliance Telix Pharma To Acquire ImaginAb to Boost Therapeutics and Innovation Roche Secures US FDA Approval for its Ultra-Sensitive ISH test Rappta Therapeutics and SpringWorks Partner on Molecular Glue Targeting PP2A Taro Pharma To Acquire entire stake in Antibe Therapeutics Innovent Biologics Secures Breakthrough Therapy Designation for IBI343 Emcure Pharma Launches Largest R&D Centre in Ahmedabad Zydus Bags USFDA Nod for Phase II(b) Trial to Optimize Usnoflast Dosage US FDA Approves Amgen's Lumakras-Vectibix Combo for KRAS G12C-Mutated mCRC Glenmark Pharma Unveils generic anticoagulant injectable emulsion Strides Pharma Bags USFDA Nod for OTC Acetaminophen-Ibuprofen Combo Tablets US FDA Lifts Hold on Sanofi's Trial to Make Cialis Available Over-the-Counter Hoth Therapeutics Expands Intellectual Property with New Patents Jaguar Health Starts POC Trial of Crofelemer for Rare Pediatric Disease MVID Pharma and Healthcare Sector Eyes Union Budget 2025 for Innovation Boost How Innovative Drug Formulations are Enhancing Treatment Outcomes Apollo and Mayapada Healthcare Unite to Boost Indonesia's Healthcare Novo Nordisk Reports Positive Phase 1b/2a Results for Amycretin Govt to Extend Schedule M Compliance Deadline for Drug Manufacturers to Dec Lupin Secures US FDA Nod for Ipratropium Bromide Nasal Solution ANDA Granules Pharmaceuticals Secures USFDA Nod for Key Generic Drug Bajaj Healthcare Bags DCGI Nod to Manufacture Pimavanserin API & Formulation Union Budget 2025: Healthcare Gets 9.78% Boost, Allocation Nears 1 Lakh Crore Metropolis & Roche Launch Self-Sampling HPV Test for Cervical Cancer Sigachi Industries Invests $1M in Hyderabad R&D Hub for API Innovation Pharma Testing Market Surges with Rising Demand for Biologics ISTH Releases Clinical Practice Guideline For Haemophilia Treatment Sanofi and Biovac Lead Polio Vaccine Manufacturing Capabilities Sun Pharma and Takeda Ink Pact To Market Gastrointestinal Drug Takeda and Ascentage Pharma Ink Option Agreement For Olverembatinib Enhancing Compliance through Effective Pharmaceutical Regulatory Affairs Strategies India poised to become a Global Hub for Clinical Trials: Exec SCHOTT Pharma Unveils Next-Gen Polymer Syringes for Enhanced Safety GSK's Jemperli Gains EU Nod for First-Line Treatment of Endometrial Cancer Union Health Secretary Urges Stronger Drug Regulations for Quality Control Telangana Govt Inks Landmark Deals to Propel Life Sciences and Job Growth R&D in Indian Pharma: Breakthroughs and Innovations in 2024 Dr. Reddy's Partners with Shanghai Henlius to Develop Cancer Drug Uniphar Expands Global Footprint with Three New Facilities 74th Indian Pharmaceutical Congress 2025 Opens Registrations AGC Pharma Expands HPAPI Capabilities in Barcelona to Meet Growing Demand The Future of Genomic Sequencing: Trends That Will Define the Next Decade Lexaria Bioscience Ethics Review Board Nod to Commence New GLP-1 Study Amitabh Kant Urges India to Focus on Innovation at BioAsia 2025 Government Enhances Research & Integration Initiatives in Unani Medicine Blind & Deaf individuals face Major Barriers to access Medicines: Report C-CAMP and PariSante Campus launched Indo-French Life Sciences Hub Jaguar Health Begins Pediatric Trial for Crofelemer in Short Bowel Syndrome Algiax Pharma Reports Promising Phase 2a Results for AP-325 Govt Bans 34 Antimicrobials for Use in Animals Pharmaceutical Procurement Strategies: How to Optimize Costs Personalized Medicine: Get Tailored Treatment Plans for You Now How to Bridge the Healthcare Gap in Emerging Markets with MedTech The Evolution of In-Vitro Diagnostics: Trends and Future Prospects Needle-Free Injection System: A Game Changer in Less Pain Vaccination How Global Capability Centers are Shaping the Future of Biometrics Building a Successful Pharma Brand in India: The Role of Scientific Communication Unlocking India's Innovation Potential in Pharma The Future of Green Chemistry in API Production Top 10 Pharmaceutical Recruitment Consultants - 2024 | Pharma Outlook Blockchain for Secure Pharmaceutical Supply Chains - 2025 & Beyond Mass Spectrometry in Biomarker Discovery for Early Disease Detection Iconovo and Lonza Team up to Advance Intranasal Biologic with ICOone Nasal Fetal Imaging to Cardiac Diagnosis: The Expanding Role of Ultrasound Balancing Innovation and Affordability in Medical Solutions for India Changing Landscape for LTBI and Syndromic Testing Methodologies How Advanced Training Methods can Enhance Patient Care Balancing Cost Efficiency and Compliance in Pharmaceutical Manufacturing LUB Urges Govt to Scrap Mandatory Lab Testing for Cough Syrup Exports Role of Optical Imaging in Early Cancer Detection and Treatment Hoth Therapeutics Unveils Promising Data for KIT-Targeting Therapy Pharmexcil Engages ASEAN Nations to Boost Pharma Trade Ties Fortis Partners with Teleflex for South Asia UroLift Training Anti-Infectives: How New Research is Shaping Infection Control Building Bridges for Sustainable Growth through Strategic Alliances in Ethical Pharmaceuticals Quality as the Cornerstone of Lab Solutions FDA Approves Roch's NSCLC Diagnostic Linked to Emrelis How Early Detection is Transforming Cancer Treatment in India Ensuring Data Privacy in Pharma World Enhancing Clinical Trial Supply Chain Resilience to Address Global Disruptions in India Cost-Effectiveness of Minimally Invasive Surgery in Outpatient Settings How Organic Synthesis is Accelerating Drug Discovery in Pharma Strategic finance for pharmaceutical innovation and stability Top 10 Teleradiology Service Providers - 2024 | Pharma Outlook Importance of Investing in R&D and Quality for Competitive Advantage in Eye Care Top 10 In Vitro Diagnostics Companies - 2024 | Pharma Outlook Phytopharmaceuticals: Driving Global Herbal Medicine Innovation Gender Gap in Healthcare: Why Women's Health Needs More Research Impact of Modern Technology on the Indian Life Sciences Sector Why Global Pharma Expects CDMOs to Be Ready for Joint Inspections The Role of Customizable Stent Grafts for Treating Complex Anatomies Nutraceuticals vs Pharmaceuticals: Complementary or Alternative in Chronic Disease Management? Top 10 Pharma CDMO Companies In India – 2023 | Pharma Outlook Leaping Towards Global Compliance with Revised Schedule M Meril Concludes TechVentory, Boosts AI-Driven Healthcare Supply Chains 10 Pharma Sector Revolutions in India Standardizing Medicine Labeling and Embracing Digital Transformation Creating a patient-centric healthcare ecosystem for all Biomanufacturing of Enzymes: A Sustainable Approach to Industrial Biotechnology Integrating CSR into HR Practices to Enhance Brand Reputation in Pharma Merck Launches Phase 3 Trial for Promising Dengue Vaccine V181 Breakthrough: Eye-Opening Healthcare Strategies Doctors Swear By on Doctor's Day 2025 Bristol Myers Squibb Reports Strong Phase 3 Results for Deucravacitinib trail Alcon Launches Innovative Daily Lenses Designed for Long-lasting Comfort Apisolex Excipient by Lubrizol Backs Phase I Drug Success FDA Approves Enflonsia to Prevent RSV in Infants with One Dose Biosimilars in India 2025 Market Trends, Growth Forecast & Opportunities How Regulations Are Shaping India's Medical Device Landscape Bharat Biotech Partners with GSK for Shigella Vaccine Development Eli Lilly Obesity Drug Shows 11.5% Weight Loss in 12 Weeks Laborate Pharmaceuticals: Illuminating Pathways Of Quality, Affordability Innovation In Healthcare Sun Pharma Bags CDSCO Approval to Produce Fexuprazan Hydrochloride Tablets The Fusion of Biology, Medicine, Health, and AI Glenmark Gets DCGI Nod to Launch Oncology Drug BRUKINSA in India Kyndryl Partners with Dr Reddys to Automate Global IT Operations How Robotic Assisted Surgery Is Redefining Precision in Kidney Transplants Top 10 Women Disruptors in Asia Pharmaceutical Industry

Editor's Guest

Related Articles


© 2025 India Pharma Outlook. All Rights Reserved.